Henry Pelish - Nuvalent Senior Discovery
| NUVL Stock | USD 96.68 0.08 0.08% |
Executive
Henry Pelish is Senior Discovery of Nuvalent
| Address | One Broadway, Cambridge, MA, United States, 02142 |
| Phone | 857 357 7000 |
| Web | https://www.nuvalent.com |
Henry Pelish Latest Insider Activity
Tracking and analyzing the buying and selling activities of Henry Pelish against Nuvalent stock is an integral part of due diligence when investing in Nuvalent. Henry Pelish insider activity provides valuable insight into whether Nuvalent is net buyers or sellers over its current business cycle. Note, Nuvalent insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nuvalent'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Henry Pelish over three months ago Disposition of 28900 shares by Henry Pelish of Nuvalent at 72.35 subject to Rule 16b-3 |
Nuvalent Management Efficiency
The company has return on total asset (ROA) of (0.1863) % which means that it has lost $0.1863 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2957) %, meaning that it created substantial loss on money invested by shareholders. Nuvalent's management efficiency ratios could be used to measure how well Nuvalent manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.18. Return On Capital Employed is expected to rise to -0.2 this year. At this time, Nuvalent's Total Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 559 M this year, although the value of Other Current Assets will most likely fall to about 4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Nivi Nehra | Travere Therapeutics | N/A | |
| Leigh Peterson | United Therapeutics | N/A | |
| Naomi Eichenbaum | Travere Therapeutics | N/A | |
| Christopher CFA | Travere Therapeutics | 39 | |
| Janet Graesser | Vaxcyte | N/A | |
| Mei Jang | Kiniksa Pharmaceuticals | N/A | |
| John Jordan | Viridian Therapeutics | N/A | |
| FACC MD | Kiniksa Pharmaceuticals | 59 | |
| Charlotte Smith | Travere Therapeutics | N/A | |
| MBA MD | Replimune Group | 58 | |
| Xichen Lin | Structure Therapeutics American | 50 | |
| Matthew Moore | Ventyx Biosciences | 51 | |
| Xinglong Jiang | Structure Therapeutics American | N/A | |
| Carsten Boess | Kiniksa Pharmaceuticals | 58 | |
| Harp MBA | Vaxcyte | 51 | |
| Mary CPA | Cullinan Oncology LLC | 60 | |
| Helen Milton | Viridian Therapeutics | N/A | |
| Michael CPA | Kiniksa Pharmaceuticals | 53 | |
| Kevin Gray | United Therapeutics | N/A | |
| Shan Wu | Viridian Therapeutics | N/A | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.19 |
Nuvalent Leadership Team
Elected by the shareholders, the Nuvalent's board of directors comprises two types of representatives: Nuvalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nuvalent. The board's role is to monitor Nuvalent's management team and ensure that shareholders' interests are well served. Nuvalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nuvalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Porter, President CEO | ||
| Darlene Noci, Chief Officer | ||
| Perrin BS, Senior Strategy | ||
| Prof Shair, Head Founder | ||
| John Soglia, Senior Development | ||
| Christopher MD, Chief Officer | ||
| Deborah JD, Chief Secretary | ||
| Benjamin Lane, Senior Operations | ||
| Henry Pelish, Senior Discovery | ||
| Matthew Metivier, Senior Resources |
Nuvalent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nuvalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 5.7 B | ||||
| Shares Outstanding | 65.62 M | ||||
| Shares Owned By Insiders | 2.83 % | ||||
| Shares Owned By Institutions | 97.17 % | ||||
| Number Of Shares Shorted | 4.9 M | ||||
| Price To Earning | (0.06) X | ||||
| Price To Book | 6.13 X | ||||
| EBITDA | (149.49 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvalent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more information on how to buy Nuvalent Stock please use our How to buy in Nuvalent Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvalent. If investors know Nuvalent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvalent listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.49) | Return On Assets (0.19) | Return On Equity (0.30) |
The market value of Nuvalent is measured differently than its book value, which is the value of Nuvalent that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvalent's value that differs from its market value or its book value, called intrinsic value, which is Nuvalent's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvalent's market value can be influenced by many factors that don't directly affect Nuvalent's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvalent's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvalent is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.